Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ariad Pharmaceuticals, Inc. (ARIA) To Seek Regulatory Clearance For Brigatinib In 3Q

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has said that it will file a new drug application (NDA) for its pipeline candidate brigatinib in 3Q2016. This followed a presentation of pivotal Phase 2 data for the compound at the ASCO conference. According to Ariad, brigatinib showed impressive results in ALK+ lung cancer patients who received it during the study. Those patients had experienced a progression of their disease condition even after receiving Pfizer Inc. (NYSE:PFE) drug Xalkori.

Ariad said that it has already initiated a Phase 3 study of brigatinib that will focus primarily on evaluating the efficacy of the compound against Xalkori from Pfizer.

The outcome of brigatinib therapy

According to Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), the median progression-free survival in patients who received brigatinib after they failed Xalkori treatment was more than one year at 12.9 months. Moreover, 67% of brain metastases sufferers who took brigatinib demonstrated a favorable objective response rate.


Regulatory filing

Following the positive findings in the Phase 2 study of brigatinib in ALK+NSCLC patients, Ariad now feels more confident about facing regulators with a new drug application for the compound. The company said it plans to submit an NDA for brigatinib to the Food and Drug Administration in 3Q2016. The hope for positive feedback by Ariad appears to be supported by the fact that brigatinib already enjoys U.S. Orphan Drug status and Breakthrough Therapy status for the treatment of ALK+NSCLC.

Pipeline candidates

Besides brigatinib, Ariad Pharmaceuticals’ other pipeline candidate is AP32788, which is currently in a Phase 1/2 study. AP32788 is being developed as a treatment for certain specific conditions and variants of NSCLC.

Beyond AP32788 and brigatinib, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has a marketable drug called Iclusig, which targets leukemia. Therefore, success with brigatinib should further widen revenue opportunity for the biotech.

Follow Ariad Pharmaceuticals Inc (NASDAQ:ARIA)
Trade (NASDAQ:ARIA) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.